TWI698445B - 微型ｒｎａ化合物及調控ｍｉｒ－２１活性之方法 - Google Patents

微型ｒｎａ化合物及調控ｍｉｒ－２１活性之方法 Download PDF

Info

Publication number: TWI698445B
Authority: TW; Taiwan
Prior art keywords: nucleoside; certain embodiments; mir; fibrosis; nucleosides
Prior art date: 2011-04-25

Application number

TW106131684A

Other languages

English (en)

Chinese (zh)

Other versions

TW201811812A (zh

Inventor

巴克利斯翰巴特

Original Assignee

法商賽諾菲公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-25

Filing date

2012-04-25

Publication date

2020-07-11

2012-04-25 Application filed by 法商賽諾菲公司 filed Critical 法商賽諾菲公司

2018-04-01 Publication of TW201811812A publication Critical patent/TW201811812A/zh

2020-07-11 Application granted granted Critical

2020-07-11 Publication of TWI698445B publication Critical patent/TWI698445B/zh

Links

108091062762 miR-21 stem-loop Proteins 0.000 title claims abstract description 182
108091041631 miR-21-1 stem-loop Proteins 0.000 title claims abstract description 180
108091044442 miR-21-2 stem-loop Proteins 0.000 title claims abstract description 180
230000000694 effects Effects 0.000 title claims abstract description 75
150000001875 compounds Chemical class 0.000 title claims description 250
238000000034 method Methods 0.000 title abstract description 104
108091070501 miRNA Proteins 0.000 title description 11
239000002777 nucleoside Substances 0.000 claims abstract description 814
150000003833 nucleoside derivatives Chemical class 0.000 claims abstract description 416
206010016654 Fibrosis Diseases 0.000 claims abstract description 119
230000004761 fibrosis Effects 0.000 claims abstract description 116
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 67
201000010099 disease Diseases 0.000 claims abstract description 59
239000003112 inhibitor Substances 0.000 claims abstract description 37
230000014509 gene expression Effects 0.000 claims abstract description 20
108091034117 Oligonucleotide Proteins 0.000 claims description 253
125000003835 nucleoside group Chemical group 0.000 claims description 212
-1 bicyclic nucleoside Chemical class 0.000 claims description 135
230000000295 complement effect Effects 0.000 claims description 91
210000004027 cell Anatomy 0.000 claims description 67
108010035532 Collagen Proteins 0.000 claims description 60
102000008186 Collagen Human genes 0.000 claims description 60
229920001436 collagen Polymers 0.000 claims description 60
239000005549 deoxyribonucleoside Substances 0.000 claims description 55
238000011282 treatment Methods 0.000 claims description 50
239000003814 drug Substances 0.000 claims description 30
210000004185 liver Anatomy 0.000 claims description 30
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 27
210000000056 organ Anatomy 0.000 claims description 24
210000001519 tissue Anatomy 0.000 claims description 24
239000002342 ribonucleoside Substances 0.000 claims description 22
229940079593 drug Drugs 0.000 claims description 21
238000000338 in vitro Methods 0.000 claims description 21
230000003908 liver function Effects 0.000 claims description 21
238000001727 in vivo Methods 0.000 claims description 20
210000002950 fibroblast Anatomy 0.000 claims description 18
230000006870 function Effects 0.000 claims description 18
201000002793 renal fibrosis Diseases 0.000 claims description 17
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims description 16
230000001684 chronic effect Effects 0.000 claims description 16
210000003734 kidney Anatomy 0.000 claims description 14
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 14
239000002260 anti-inflammatory agent Substances 0.000 claims description 13
229940121363 anti-inflammatory agent Drugs 0.000 claims description 13
229940104302 cytosine Drugs 0.000 claims description 13
RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 13
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 12
239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 11
208000020832 chronic kidney disease Diseases 0.000 claims description 11
208000014674 injury Diseases 0.000 claims description 11
229960002198 irbesartan Drugs 0.000 claims description 11
YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 11
208000005069 pulmonary fibrosis Diseases 0.000 claims description 11
230000003907 kidney function Effects 0.000 claims description 10
230000009787 cardiac fibrosis Effects 0.000 claims description 9
230000004217 heart function Effects 0.000 claims description 9
208000019425 cirrhosis of liver Diseases 0.000 claims description 8
229960002474 hydralazine Drugs 0.000 claims description 8
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 7
206010039710 Scleroderma Diseases 0.000 claims description 7
208000035475 disorder Diseases 0.000 claims description 7
229960002490 fosinopril Drugs 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
238000002054 transplantation Methods 0.000 claims description 7
102000008873 Angiotensin II receptor Human genes 0.000 claims description 6
108050000824 Angiotensin II receptor Proteins 0.000 claims description 6
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 6
239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 6
239000004072 C09CA03 - Valsartan Substances 0.000 claims description 6
239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 6
108010061435 Enalapril Proteins 0.000 claims description 6
208000022461 Glomerular disease Diseases 0.000 claims description 6
108010007859 Lisinopril Proteins 0.000 claims description 6
230000001154 acute effect Effects 0.000 claims description 6
229940125708 antidiabetic agent Drugs 0.000 claims description 6
239000003472 antidiabetic agent Substances 0.000 claims description 6
229960004530 benazepril Drugs 0.000 claims description 6
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 6
229960000873 enalapril Drugs 0.000 claims description 6
229960004563 eprosartan Drugs 0.000 claims description 6
OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 6
230000000893 fibroproliferative effect Effects 0.000 claims description 6
206010061989 glomerulosclerosis Diseases 0.000 claims description 6
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 6
229960000201 isosorbide dinitrate Drugs 0.000 claims description 6
229960002394 lisinopril Drugs 0.000 claims description 6
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 6
208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 6
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims description 6
229960001455 quinapril Drugs 0.000 claims description 6
229960003401 ramipril Drugs 0.000 claims description 6
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 6
229960005187 telmisartan Drugs 0.000 claims description 6
229960004699 valsartan Drugs 0.000 claims description 6
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 6
101800000733 Angiotensin-2 Proteins 0.000 claims description 5
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 5
102000004190 Enzymes Human genes 0.000 claims description 5
108090000790 Enzymes Proteins 0.000 claims description 5
229920001499 Heparinoid Polymers 0.000 claims description 5
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 5
206010061481 Renal injury Diseases 0.000 claims description 5
229950006323 angiotensin ii Drugs 0.000 claims description 5
229960000830 captopril Drugs 0.000 claims description 5
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical group SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 5
206010012601 diabetes mellitus Diseases 0.000 claims description 5
229960005156 digoxin Drugs 0.000 claims description 5
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 5
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 5
239000002554 heparinoid Substances 0.000 claims description 5
239000003018 immunosuppressive agent Substances 0.000 claims description 5
208000037806 kidney injury Diseases 0.000 claims description 5
230000004199 lung function Effects 0.000 claims description 5
229940124597 therapeutic agent Drugs 0.000 claims description 5
239000002083 C09CA01 - Losartan Substances 0.000 claims description 4
239000002053 C09CA06 - Candesartan Substances 0.000 claims description 4
229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
206010018364 Glomerulonephritis Diseases 0.000 claims description 4
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 4
206010023424 Kidney infection Diseases 0.000 claims description 4
206010067125 Liver injury Diseases 0.000 claims description 4
108020001621 Natriuretic Peptide Proteins 0.000 claims description 4
102000004571 Natriuretic peptide Human genes 0.000 claims description 4
239000005480 Olmesartan Substances 0.000 claims description 4
206010037596 Pyelonephritis Diseases 0.000 claims description 4
206010050207 Skin fibrosis Diseases 0.000 claims description 4
206010072207 Splenic fibrosis Diseases 0.000 claims description 4
239000002876 beta blocker Substances 0.000 claims description 4
229940097320 beta blocking agent Drugs 0.000 claims description 4
239000000480 calcium channel blocker Substances 0.000 claims description 4
229960000932 candesartan Drugs 0.000 claims description 4
SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 4
208000036971 interstitial lung disease 2 Diseases 0.000 claims description 4
229960004773 losartan Drugs 0.000 claims description 4
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 4
239000000692 natriuretic peptide Substances 0.000 claims description 4
150000002823 nitrates Chemical class 0.000 claims description 4
229960005117 olmesartan Drugs 0.000 claims description 4
VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims description 4
230000000306 recurrent effect Effects 0.000 claims description 4
230000008733 trauma Effects 0.000 claims description 4
229940124549 vasodilator Drugs 0.000 claims description 4
239000003071 vasodilator agent Substances 0.000 claims description 4
206010003694 Atrophy Diseases 0.000 claims description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
206010018372 Glomerulonephritis membranous Diseases 0.000 claims description 3
208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
206010021263 IgA nephropathy Diseases 0.000 claims description 3
230000037444 atrophy Effects 0.000 claims description 3
231100000012 chronic liver injury Toxicity 0.000 claims description 3
208000028208 end stage renal disease Diseases 0.000 claims description 3
201000000523 end stage renal failure Diseases 0.000 claims description 3
231100000852 glomerular disease Toxicity 0.000 claims description 3
208000006454 hepatitis Diseases 0.000 claims description 3
231100000283 hepatitis Toxicity 0.000 claims description 3
230000003463 hyperproliferative effect Effects 0.000 claims description 3
208000015181 infectious disease Diseases 0.000 claims description 3
201000008350 membranous glomerulonephritis Diseases 0.000 claims description 3
231100000855 membranous nephropathy Toxicity 0.000 claims description 3
108010039419 Connective Tissue Growth Factor Proteins 0.000 claims description 2
102000015225 Connective Tissue Growth Factor Human genes 0.000 claims description 2
206010021143 Hypoxia Diseases 0.000 claims description 2
230000001146 hypoxic effect Effects 0.000 claims description 2
229960003444 immunosuppressant agent Drugs 0.000 claims description 2
230000001861 immunosuppressant effect Effects 0.000 claims description 2
210000002510 keratinocyte Anatomy 0.000 claims description 2
206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
230000036961 partial effect Effects 0.000 claims description 2
239000005541 ACE inhibitor Substances 0.000 claims 2
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
102000005862 Angiotensin II Human genes 0.000 claims 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 1
208000034189 Sclerosis Diseases 0.000 claims 1
235000009508 confectionery Nutrition 0.000 claims 1
229940025770 heparinoids Drugs 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 abstract description 80
201000011510 cancer Diseases 0.000 abstract description 49
239000000203 mixture Substances 0.000 abstract description 38
230000004048 modification Effects 0.000 abstract description 32
238000012986 modification Methods 0.000 abstract description 32
230000002159 abnormal effect Effects 0.000 abstract description 21
230000005764 inhibitory process Effects 0.000 abstract description 19
230000003389 potentiating effect Effects 0.000 abstract description 2
235000000346 sugar Nutrition 0.000 description 89
108700011259 MicroRNAs Proteins 0.000 description 69
239000008194 pharmaceutical composition Substances 0.000 description 64
239000003795 chemical substances by application Substances 0.000 description 46
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 42
239000008177 pharmaceutical agent Substances 0.000 description 41
210000004369 blood Anatomy 0.000 description 38
239000008280 blood Substances 0.000 description 38
102000039446 nucleic acids Human genes 0.000 description 32
108020004707 nucleic acids Proteins 0.000 description 32
150000007523 nucleic acids Chemical class 0.000 description 32
230000001105 regulatory effect Effects 0.000 description 30
208000004608 Ureteral Obstruction Diseases 0.000 description 29
238000002560 therapeutic procedure Methods 0.000 description 28
108020004999 messenger RNA Proteins 0.000 description 27
230000004083 survival effect Effects 0.000 description 27
239000002585 base Substances 0.000 description 23
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 22
125000002619 bicyclic group Chemical group 0.000 description 22
208000009304 Acute Kidney Injury Diseases 0.000 description 20
208000033626 Renal failure acute Diseases 0.000 description 20
238000004458 analytical method Methods 0.000 description 20
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 20
201000007270 liver cancer Diseases 0.000 description 20
208000014018 liver neoplasm Diseases 0.000 description 20
241001465754 Metazoa Species 0.000 description 19
206010063837 Reperfusion injury Diseases 0.000 description 19
201000011040 acute kidney failure Diseases 0.000 description 19
238000009472 formulation Methods 0.000 description 18
206010073071 hepatocellular carcinoma Diseases 0.000 description 18
231100000844 hepatocellular carcinoma Toxicity 0.000 description 18
230000002401 inhibitory effect Effects 0.000 description 18
239000002773 nucleotide Substances 0.000 description 17
230000008569 process Effects 0.000 description 17
206010027476 Metastases Diseases 0.000 description 16
208000012947 ischemia reperfusion injury Diseases 0.000 description 16
230000009401 metastasis Effects 0.000 description 16
238000012360 testing method Methods 0.000 description 15
238000002347 injection Methods 0.000 description 14
239000007924 injection Substances 0.000 description 14
108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
108060001084 Luciferase Proteins 0.000 description 13
239000005089 Luciferase Substances 0.000 description 13
241000699670 Mus sp. Species 0.000 description 13
208000027418 Wounds and injury Diseases 0.000 description 13
238000002474 experimental method Methods 0.000 description 13
125000003843 furanosyl group Chemical group 0.000 description 13
239000002243 precursor Substances 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 12
101150006308 botA gene Proteins 0.000 description 12
230000006378 damage Effects 0.000 description 12
230000007423 decrease Effects 0.000 description 12
150000002632 lipids Chemical group 0.000 description 12
210000004072 lung Anatomy 0.000 description 12
125000003729 nucleotide group Chemical group 0.000 description 12
229940002612 prodrug Drugs 0.000 description 12
239000000651 prodrug Substances 0.000 description 12
239000000126 substance Substances 0.000 description 12
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 11
238000013059 nephrectomy Methods 0.000 description 11
238000007920 subcutaneous administration Methods 0.000 description 11
108010088751 Albumins Proteins 0.000 description 10
102000009027 Albumins Human genes 0.000 description 10
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 10
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 10
241000282414 Homo sapiens Species 0.000 description 10
230000008859 change Effects 0.000 description 10
229940109239 creatinine Drugs 0.000 description 10
210000002744 extracellular matrix Anatomy 0.000 description 10
208000005374 Poisoning Diseases 0.000 description 9
210000002216 heart Anatomy 0.000 description 9
238000001990 intravenous administration Methods 0.000 description 9
108091007426 microRNA precursor Proteins 0.000 description 9
231100000572 poisoning Toxicity 0.000 description 9
230000000607 poisoning effect Effects 0.000 description 9
210000005084 renal tissue Anatomy 0.000 description 9
150000008163 sugars Chemical class 0.000 description 9
238000012384 transportation and delivery Methods 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
230000029663 wound healing Effects 0.000 description 9
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 8
108020004414 DNA Proteins 0.000 description 8
125000000217 alkyl group Chemical group 0.000 description 8
239000003246 corticosteroid Substances 0.000 description 8
229960004397 cyclophosphamide Drugs 0.000 description 8
210000002919 epithelial cell Anatomy 0.000 description 8
230000007705 epithelial mesenchymal transition Effects 0.000 description 8
125000000623 heterocyclic group Chemical group 0.000 description 8
208000017169 kidney disease Diseases 0.000 description 8
208000019423 liver disease Diseases 0.000 description 8
239000000243 solution Substances 0.000 description 8
125000001424 substituent group Chemical group 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 7
101710163270 Nuclease Proteins 0.000 description 7
108090000340 Transaminases Proteins 0.000 description 7
102000003929 Transaminases Human genes 0.000 description 7
238000011319 anticancer therapy Methods 0.000 description 7
125000003118 aryl group Chemical group 0.000 description 7
239000002775 capsule Substances 0.000 description 7
238000002591 computed tomography Methods 0.000 description 7
239000006184 cosolvent Substances 0.000 description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
239000002679 microRNA Substances 0.000 description 7
229910052757 nitrogen Inorganic materials 0.000 description 7
108091027963 non-coding RNA Proteins 0.000 description 7
102000042567 non-coding RNA Human genes 0.000 description 7
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
239000000725 suspension Substances 0.000 description 7
230000008685 targeting Effects 0.000 description 7
210000002700 urine Anatomy 0.000 description 7
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
102100023635 Alpha-fetoprotein Human genes 0.000 description 6
206010003445 Ascites Diseases 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
208000014644 Brain disease Diseases 0.000 description 6
102100027378 Prothrombin Human genes 0.000 description 6
108010094028 Prothrombin Proteins 0.000 description 6
206010052428 Wound Diseases 0.000 description 6
125000000304 alkynyl group Chemical group 0.000 description 6
108010026331 alpha-Fetoproteins Proteins 0.000 description 6
239000004037 angiogenesis inhibitor Substances 0.000 description 6
208000019622 heart disease Diseases 0.000 description 6
238000009396 hybridization Methods 0.000 description 6
239000007788 liquid Substances 0.000 description 6
239000007937 lozenge Substances 0.000 description 6
210000001165 lymph node Anatomy 0.000 description 6
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
239000001267 polyvinylpyrrolidone Substances 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
239000000047 product Substances 0.000 description 6
229940039716 prothrombin Drugs 0.000 description 6
230000009467 reduction Effects 0.000 description 6
230000008439 repair process Effects 0.000 description 6
239000003381 stabilizer Substances 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
229960005486 vaccine Drugs 0.000 description 6
230000002861 ventricular Effects 0.000 description 6
125000004400 (C1-C12) alkyl group Chemical group 0.000 description 5
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 5
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
108010082126 Alanine transaminase Proteins 0.000 description 5
108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 5
208000032274 Encephalopathy Diseases 0.000 description 5
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
206010022095 Injection Site reaction Diseases 0.000 description 5
239000005551 L01XE03 - Erlotinib Substances 0.000 description 5
239000005511 L01XE05 - Sorafenib Substances 0.000 description 5
208000019693 Lung disease Diseases 0.000 description 5
229910019142 PO4 Inorganic materials 0.000 description 5
239000002202 Polyethylene glycol Substances 0.000 description 5
238000010171 animal model Methods 0.000 description 5
239000000090 biomarker Substances 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
230000000747 cardiac effect Effects 0.000 description 5
210000002808 connective tissue Anatomy 0.000 description 5
238000013461 design Methods 0.000 description 5
239000008298 dragée Substances 0.000 description 5
229960001904 epirubicin Drugs 0.000 description 5
229960001433 erlotinib Drugs 0.000 description 5
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 5
229960005420 etoposide Drugs 0.000 description 5
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 5
150000002243 furanoses Chemical group 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
230000001394 metastastic effect Effects 0.000 description 5
206010061289 metastatic neoplasm Diseases 0.000 description 5
239000010452 phosphate Substances 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
229960003787 sorafenib Drugs 0.000 description 5
230000000087 stabilizing effect Effects 0.000 description 5
235000021092 sugar substitutes Nutrition 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
239000003765 sweetening agent Substances 0.000 description 5
229910052720 vanadium Inorganic materials 0.000 description 5
YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 description 4
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 4
125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 4
125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 4
PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 4
208000035657 Abasia Diseases 0.000 description 4
102400000345 Angiotensin-2 Human genes 0.000 description 4
102000055006 Calcitonin Human genes 0.000 description 4
108060001064 Calcitonin Proteins 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
208000006029 Cardiomegaly Diseases 0.000 description 4
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical group ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 4
239000012623 DNA damaging agent Substances 0.000 description 4
201000010046 Dilated cardiomyopathy Diseases 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
108010009202 Growth Factor Receptors Proteins 0.000 description 4
102000009465 Growth Factor Receptors Human genes 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 4
239000005411 L01XE02 - Gefitinib Substances 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
230000004913 activation Effects 0.000 description 4
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
229940121369 angiogenesis inhibitor Drugs 0.000 description 4
230000003432 anti-folate effect Effects 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
229940127074 antifolate Drugs 0.000 description 4
239000002246 antineoplastic agent Substances 0.000 description 4
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 4
229960000397 bevacizumab Drugs 0.000 description 4
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 4
229960004015 calcitonin Drugs 0.000 description 4
229960004562 carboplatin Drugs 0.000 description 4
230000033077 cellular process Effects 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
230000007882 cirrhosis Effects 0.000 description 4
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
229960004316 cisplatin Drugs 0.000 description 4
229940127089 cytotoxic agent Drugs 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
238000009826 distribution Methods 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
229940011871 estrogen Drugs 0.000 description 4
239000000262 estrogen Substances 0.000 description 4
239000000835 fiber Substances 0.000 description 4
239000000796 flavoring agent Substances 0.000 description 4
229910052731 fluorine Inorganic materials 0.000 description 4
239000004052 folic acid antagonist Substances 0.000 description 4
229960002584 gefitinib Drugs 0.000 description 4
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
229940014259 gelatin Drugs 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
229930182470 glycoside Natural products 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 4
229960001101 ifosfamide Drugs 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
230000000968 intestinal effect Effects 0.000 description 4
238000007918 intramuscular administration Methods 0.000 description 4
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 4
229960004768 irinotecan Drugs 0.000 description 4
229940043355 kinase inhibitor Drugs 0.000 description 4
239000008101 lactose Substances 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
239000002502 liposome Substances 0.000 description 4
238000007449 liver function test Methods 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000010172 mouse model Methods 0.000 description 4
208000010125 myocardial infarction Diseases 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000012071 phase Substances 0.000 description 4
239000003757 phosphotransferase inhibitor Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
238000001959 radiotherapy Methods 0.000 description 4
239000002336 ribonucleotide Substances 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
238000004904 shortening Methods 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
238000009423 ventilation Methods 0.000 description 4
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 3
102400000068 Angiostatin Human genes 0.000 description 3
108010079709 Angiostatins Proteins 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
208000003174 Brain Neoplasms Diseases 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
206010007572 Cardiac hypertrophy Diseases 0.000 description 3
206010009208 Cirrhosis alcoholic Diseases 0.000 description 3
206010009944 Colon cancer Diseases 0.000 description 3
206010056370 Congestive cardiomyopathy Diseases 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
102400001047 Endostatin Human genes 0.000 description 3
108010079505 Endostatins Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108060002716 Exonuclease Proteins 0.000 description 3
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
208000017604 Hodgkin disease Diseases 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 3
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
239000002147 L01XE04 - Sunitinib Substances 0.000 description 3
239000002067 L01XE06 - Dasatinib Substances 0.000 description 3
239000002136 L01XE07 - Lapatinib Substances 0.000 description 3
239000003798 L01XE11 - Pazopanib Substances 0.000 description 3
239000002118 L01XE12 - Vandetanib Substances 0.000 description 3
102000003960 Ligases Human genes 0.000 description 3
108090000364 Ligases Proteins 0.000 description 3
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
208000021642 Muscular disease Diseases 0.000 description 3
201000009623 Myopathy Diseases 0.000 description 3
206010029155 Nephropathy toxic Diseases 0.000 description 3
208000005736 Nervous System Malformations Diseases 0.000 description 3
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
108060008245 Thrombospondin Proteins 0.000 description 3
102000002938 Thrombospondin Human genes 0.000 description 3
240000001717 Vaccinium macrocarpon Species 0.000 description 3
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
230000005856 abnormality Effects 0.000 description 3
239000002253 acid Substances 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
208000010002 alcoholic liver cirrhosis Diseases 0.000 description 3
125000003342 alkenyl group Chemical group 0.000 description 3
229940035676 analgesics Drugs 0.000 description 3
239000000730 antalgic agent Substances 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 3
230000017531 blood circulation Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
229960002092 busulfan Drugs 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
229960004630 chlorambucil Drugs 0.000 description 3
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
208000029742 colonic neoplasm Diseases 0.000 description 3
229940111134 coxibs Drugs 0.000 description 3
210000004748 cultured cell Anatomy 0.000 description 3
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
229960003901 dacarbazine Drugs 0.000 description 3
229960002448 dasatinib Drugs 0.000 description 3
229960000975 daunorubicin Drugs 0.000 description 3
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
230000001934 delay Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
102000013165 exonuclease Human genes 0.000 description 3
229960002949 fluorouracil Drugs 0.000 description 3
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
150000002367 halogens Chemical class 0.000 description 3
125000005842 heteroatom Chemical group 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
229960001680 ibuprofen Drugs 0.000 description 3
229960000908 idarubicin Drugs 0.000 description 3
238000003384 imaging method Methods 0.000 description 3
229940125721 immunosuppressive agent Drugs 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
238000001802 infusion Methods 0.000 description 3
238000007913 intrathecal administration Methods 0.000 description 3
208000028867 ischemia Diseases 0.000 description 3
229960004891 lapatinib Drugs 0.000 description 3
BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 3
229960002247 lomustine Drugs 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
238000003670 luciferase enzyme activity assay Methods 0.000 description 3
238000002595 magnetic resonance imaging Methods 0.000 description 3
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 3
229960004961 mechlorethamine Drugs 0.000 description 3
229960000485 methotrexate Drugs 0.000 description 3
229960004857 mitomycin Drugs 0.000 description 3
238000002156 mixing Methods 0.000 description 3
210000000651 myofibroblast Anatomy 0.000 description 3
231100000417 nephrotoxicity Toxicity 0.000 description 3
230000007694 nephrotoxicity Effects 0.000 description 3
239000003921 oil Substances 0.000 description 3
DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 3
229960001756 oxaliplatin Drugs 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229960001972 panitumumab Drugs 0.000 description 3
229960005489 paracetamol Drugs 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
229960000639 pazopanib Drugs 0.000 description 3
CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 3
229960003407 pegaptanib Drugs 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229920000728 polyester Polymers 0.000 description 3
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
229960004618 prednisone Drugs 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000003449 preventive effect Effects 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
239000003087 receptor blocking agent Substances 0.000 description 3
230000008458 response to injury Effects 0.000 description 3
230000007017 scission Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
229960001796 sunitinib Drugs 0.000 description 3
WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 3
239000000829 suppository Substances 0.000 description 3
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 3
229960005314 suramin Drugs 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
239000000454 talc Substances 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
229960004964 temozolomide Drugs 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
150000003573 thiols Chemical class 0.000 description 3
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
229960000303 topotecan Drugs 0.000 description 3
230000009466 transformation Effects 0.000 description 3
201000002327 urinary tract obstruction Diseases 0.000 description 3
229960000241 vandetanib Drugs 0.000 description 3
UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 2
125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 description 2
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 2
RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical group NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 2
208000022309 Alcoholic Liver disease Diseases 0.000 description 2
206010003658 Atrial Fibrillation Diseases 0.000 description 2
229940123208 Biguanide Drugs 0.000 description 2
229940122361 Bisphosphonate Drugs 0.000 description 2
206010005003 Bladder cancer Diseases 0.000 description 2
101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 2
102100031168 CCN family member 2 Human genes 0.000 description 2
QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical group COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
208000031229 Cardiomyopathies Diseases 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 2
244000133098 Echinacea angustifolia Species 0.000 description 2
102100031780 Endonuclease Human genes 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
238000000729 Fisher's exact test Methods 0.000 description 2
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
102000037909 Folate transporters Human genes 0.000 description 2
108091006783 Folate transporters Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102000004366 Glucosidases Human genes 0.000 description 2
108010056771 Glucosidases Proteins 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
108010043428 Glycine hydroxymethyltransferase Proteins 0.000 description 2
208000021519 Hodgkin lymphoma Diseases 0.000 description 2
208000010747 Hodgkins lymphoma Diseases 0.000 description 2
101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 2
101001121442 Homo sapiens Ubiquitin thioesterase OTU1 Proteins 0.000 description 2
102000004157 Hydrolases Human genes 0.000 description 2
108090000604 Hydrolases Proteins 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
239000005517 L01XE01 - Imatinib Substances 0.000 description 2
239000005536 L01XE08 - Nilotinib Substances 0.000 description 2
239000012097 Lipofectamine 2000 Substances 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
108091008065 MIR21 Proteins 0.000 description 2
108091030146 MiRBase Proteins 0.000 description 2
239000005462 Mubritinib Substances 0.000 description 2
MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
102000023984 PPAR alpha Human genes 0.000 description 2
206010061902 Pancreatic neoplasm Diseases 0.000 description 2
239000004264 Petrolatum Substances 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
102000004211 Platelet factor 4 Human genes 0.000 description 2
108090000778 Platelet factor 4 Proteins 0.000 description 2
DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
102000003946 Prolactin Human genes 0.000 description 2
108010057464 Prolactin Proteins 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
241000242739 Renilla Species 0.000 description 2
102000006382 Ribonucleases Human genes 0.000 description 2
108010083644 Ribonucleases Proteins 0.000 description 2
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
102000019394 Serine hydroxymethyltransferases Human genes 0.000 description 2
102000005157 Somatostatin Human genes 0.000 description 2
108010056088 Somatostatin Proteins 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
229940100389 Sulfonylurea Drugs 0.000 description 2
229940123464 Thiazolidinedione Drugs 0.000 description 2
108010022394 Threonine synthase Proteins 0.000 description 2
102000005497 Thymidylate Synthase Human genes 0.000 description 2
208000024770 Thyroid neoplasm Diseases 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
241000159243 Toxicodendron radicans Species 0.000 description 2
241000871311 Toxicodendron vernix Species 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
102100026369 Ubiquitin thioesterase OTU1 Human genes 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
108091008605 VEGF receptors Proteins 0.000 description 2
235000012545 Vaccinium macrocarpon Nutrition 0.000 description 2
235000002118 Vaccinium oxycoccus Nutrition 0.000 description 2
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
125000002015 acyclic group Chemical group 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
125000002723 alicyclic group Chemical group 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
125000006242 amine protecting group Chemical group 0.000 description 2
150000001412 amines Chemical group 0.000 description 2
125000004103 aminoalkyl group Chemical group 0.000 description 2
229960003896 aminopterin Drugs 0.000 description 2
239000003263 anabolic agent Substances 0.000 description 2
229940070021 anabolic steroids Drugs 0.000 description 2
239000003098 androgen Substances 0.000 description 2
229940030486 androgens Drugs 0.000 description 2
229940125364 angiotensin receptor blocker Drugs 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
229940125715 antihistaminic agent Drugs 0.000 description 2
239000000739 antihistaminic agent Substances 0.000 description 2
229940034982 antineoplastic agent Drugs 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
210000002469 basement membrane Anatomy 0.000 description 2
239000011648 beta-carotene Substances 0.000 description 2
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
235000013734 beta-carotene Nutrition 0.000 description 2
229960002747 betacarotene Drugs 0.000 description 2
150000004283 biguanides Chemical class 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
150000004663 bisphosphonates Chemical class 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
229960005243 carmustine Drugs 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000004700 cellular uptake Effects 0.000 description 2
229960005395 cetuximab Drugs 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
208000006990 cholangiocarcinoma Diseases 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000002648 chondrogenic effect Effects 0.000 description 2
230000007881 chronic fibrosis Effects 0.000 description 2
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
239000003086 colorant Substances 0.000 description 2
230000008602 contraction Effects 0.000 description 2
235000004634 cranberry Nutrition 0.000 description 2
239000006071 cream Substances 0.000 description 2
239000002254 cytotoxic agent Substances 0.000 description 2
231100000599 cytotoxic agent Toxicity 0.000 description 2
238000000151 deposition Methods 0.000 description 2
230000003205 diastolic effect Effects 0.000 description 2
235000015872 dietary supplement Nutrition 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
239000002934 diuretic Substances 0.000 description 2
229940030606 diuretics Drugs 0.000 description 2
229960001089 dobutamine Drugs 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
229960004679 doxorubicin Drugs 0.000 description 2
239000000975 dye Substances 0.000 description 2
235000014134 echinacea Nutrition 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
231100000317 environmental toxin Toxicity 0.000 description 2
229960001208 eplerenone Drugs 0.000 description 2
JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000010685 fatty oil Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
235000019152 folic acid Nutrition 0.000 description 2
239000011724 folic acid Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
229950005309 fostamatinib Drugs 0.000 description 2
GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 2
206010017758 gastric cancer Diseases 0.000 description 2
239000000499 gel Substances 0.000 description 2
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
229960005277 gemcitabine Drugs 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000012010 growth Effects 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
229910001385 heavy metal Inorganic materials 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
208000010710 hepatitis C virus infection Diseases 0.000 description 2
125000001072 heteroaryl group Chemical group 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 2
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
229960002411 imatinib Drugs 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
239000002955 immunomodulating agent Substances 0.000 description 2
229940121354 immunomodulator Drugs 0.000 description 2
230000003308 immunostimulating effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000012750 in vivo screening Methods 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
238000007914 intraventricular administration Methods 0.000 description 2
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 2
229960003827 isosorbide mononitrate Drugs 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 2
229960003784 lenvatinib Drugs 0.000 description 2
238000000622 liquid--liquid extraction Methods 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 2
239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
229960001924 melphalan Drugs 0.000 description 2
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
229960002237 metoprolol Drugs 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 2
229960003574 milrinone Drugs 0.000 description 2
229960001156 mitoxantrone Drugs 0.000 description 2
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
229950002212 mubritinib Drugs 0.000 description 2
ZTFBIUXIQYRUNT-MDWZMJQESA-N mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 description 2
229940035363 muscle relaxants Drugs 0.000 description 2
229960004866 mycophenolate mofetil Drugs 0.000 description 2
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
239000003158 myorelaxant agent Substances 0.000 description 2
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
238000013188 needle biopsy Methods 0.000 description 2
229960001267 nesiritide Drugs 0.000 description 2
HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
229960001346 nilotinib Drugs 0.000 description 2
HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
229940094443 oxytocics prostaglandins Drugs 0.000 description 2
201000002528 pancreatic cancer Diseases 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
239000013618 particulate matter Substances 0.000 description 2
229940043138 pentosan polysulfate Drugs 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 2
229940066842 petrolatum Drugs 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
150000004713 phosphodiesters Chemical class 0.000 description 2
125000004437 phosphorous atom Chemical group 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
230000006461 physiological response Effects 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
229940068968 polysorbate 80 Drugs 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000012545 processing Methods 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
238000004393 prognosis Methods 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
229940097325 prolactin Drugs 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
201000001474 proteinuria Diseases 0.000 description 2
210000003492 pulmonary vein Anatomy 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
229960003876 ranibizumab Drugs 0.000 description 2
238000003753 real-time PCR Methods 0.000 description 2
229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 2
238000007634 remodeling Methods 0.000 description 2
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
229960003522 roquinimex Drugs 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
229960001860 salicylate Drugs 0.000 description 2
238000012216 screening Methods 0.000 description 2
229910052711 selenium Inorganic materials 0.000 description 2
239000011669 selenium Substances 0.000 description 2
229940091258 selenium supplement Drugs 0.000 description 2
229950003647 semaxanib Drugs 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000000638 solvent extraction Methods 0.000 description 2
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
229960000553 somatostatin Drugs 0.000 description 2
231100000240 steatosis hepatitis Toxicity 0.000 description 2
239000002294 steroidal antiinflammatory agent Substances 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000005460 tetrahydrofolate Substances 0.000 description 2
CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 description 2
229960003433 thalidomide Drugs 0.000 description 2
125000005309 thioalkoxy group Chemical group 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
201000002510 thyroid cancer Diseases 0.000 description 2
229940036555 thyroid hormone Drugs 0.000 description 2
239000005495 thyroid hormone Substances 0.000 description 2
230000008467 tissue growth Effects 0.000 description 2
230000017423 tissue regeneration Effects 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
239000003440 toxic substance Substances 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
229960000575 trastuzumab Drugs 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
210000000626 ureter Anatomy 0.000 description 2
210000003932 urinary bladder Anatomy 0.000 description 2
201000005112 urinary bladder cancer Diseases 0.000 description 2
230000002792 vascular Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000019155 vitamin A Nutrition 0.000 description 2
239000011719 vitamin A Substances 0.000 description 2
229940045997 vitamin a Drugs 0.000 description 2
235000019195 vitamin supplement Nutrition 0.000 description 2
230000002747 voluntary effect Effects 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
FGODUFHTWYYOOB-UHFFFAOYSA-N 1,3-diaminopropan-2-yl dihydrogen phosphate Chemical compound NCC(CN)OP(O)(O)=O FGODUFHTWYYOOB-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
QSHACTSJHMKXTE-UHFFFAOYSA-N 2-(2-aminopropyl)-7h-purin-6-amine Chemical compound CC(N)CC1=NC(N)=C2NC=NC2=N1 QSHACTSJHMKXTE-UHFFFAOYSA-N 0.000 description 1
JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
108020005345 3' Untranslated Regions Proteins 0.000 description 1
GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
KUQZVISZELWDNZ-UHFFFAOYSA-N 3-aminopropyl dihydrogen phosphate Chemical compound NCCCOP(O)(O)=O KUQZVISZELWDNZ-UHFFFAOYSA-N 0.000 description 1
HYCSHFLKPSMPGO-UHFFFAOYSA-N 3-hydroxypropyl dihydrogen phosphate Chemical compound OCCCOP(O)(O)=O HYCSHFLKPSMPGO-UHFFFAOYSA-N 0.000 description 1
LZINOQJQXIEBNN-UHFFFAOYSA-N 4-hydroxybutyl dihydrogen phosphate Chemical compound OCCCCOP(O)(O)=O LZINOQJQXIEBNN-UHFFFAOYSA-N 0.000 description 1
OFNXOACBUMGOPC-HZYVHMACSA-N 5'-hydroxystreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](CO)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O OFNXOACBUMGOPC-HZYVHMACSA-N 0.000 description 1
UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
XYVLZAYJHCECPN-UHFFFAOYSA-N 6-aminohexyl phosphate Chemical compound NCCCCCCOP(O)(O)=O XYVLZAYJHCECPN-UHFFFAOYSA-N 0.000 description 1
XYVLZAYJHCECPN-UHFFFAOYSA-L 6-aminohexyl phosphate Chemical compound NCCCCCCOP([O-])([O-])=O XYVLZAYJHCECPN-UHFFFAOYSA-L 0.000 description 1
LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
206010054793 Arterial fibrosis Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
206010059027 Brugada syndrome Diseases 0.000 description 1
125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
235000007516 Chrysanthemum Nutrition 0.000 description 1
244000189548 Chrysanthemum x morifolium Species 0.000 description 1
102000003780 Clusterin Human genes 0.000 description 1
108090000197 Clusterin Proteins 0.000 description 1
101150008975 Col3a1 gene Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000025962 Crush injury Diseases 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
208000003037 Diastolic Heart Failure Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
102100039627 E3 ubiquitin-protein ligase RNF167 Human genes 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
240000001624 Espostoa lanata Species 0.000 description 1
235000009161 Espostoa lanata Nutrition 0.000 description 1
208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
208000007300 Fibrolamellar hepatocellular carcinoma Diseases 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
206010016803 Fluid overload Diseases 0.000 description 1
201000010915 Glioblastoma multiforme Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 1
101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
101000670535 Homo sapiens E3 ubiquitin-protein ligase RNF167 Proteins 0.000 description 1
101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
206010021137 Hypovolaemia Diseases 0.000 description 1
208000000913 Kidney Calculi Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
206010023421 Kidney fibrosis Diseases 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
208000034693 Laceration Diseases 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
208000011682 Mitral valve disease Diseases 0.000 description 1
208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
208000003445 Mouth Neoplasms Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
206010028594 Myocardial fibrosis Diseases 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
206010029148 Nephrolithiasis Diseases 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
239000012124 Opti-MEM Substances 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
208000009344 Penetrating Wounds Diseases 0.000 description 1
108091093037 Peptide nucleic acid Proteins 0.000 description 1
206010034498 Pericarditis uraemic Diseases 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
229920001100 Polydextrose Polymers 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
208000004210 Pressure Ulcer Diseases 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
206010063897 Renal ischaemia Diseases 0.000 description 1
206010038540 Renal tubular necrosis Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
108010081750 Reticulin Proteins 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
206010062129 Tongue neoplasm Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102100031013 Transgelin Human genes 0.000 description 1
206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
208000000558 Varicose Ulcer Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000003869 acetamides Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
229940040563 agaric acid Drugs 0.000 description 1
239000000809 air pollutant Substances 0.000 description 1
231100001243 air pollutant Toxicity 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
210000001132 alveolar macrophage Anatomy 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
WRPCDQFKIDRUIU-UHFFFAOYSA-N aniline furan Chemical compound C=1C=COC=1.NC1=CC=CC=C1 WRPCDQFKIDRUIU-UHFFFAOYSA-N 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
150000004056 anthraquinones Chemical class 0.000 description 1
239000003908 antipruritic agent Substances 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
239000010425 asbestos Substances 0.000 description 1
239000003212 astringent agent Substances 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940076134 benzene Drugs 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
229940017687 beta-d-ribose Drugs 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
210000000013 bile duct Anatomy 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229920005557 bromobutyl Polymers 0.000 description 1
229910052793 cadmium Inorganic materials 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
239000012830 cancer therapeutic Substances 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
229960004195 carvedilol Drugs 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000030833 cell death Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
231100000481 chemical toxicant Toxicity 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
208000016350 chronic hepatitis B virus infection Diseases 0.000 description 1
208000020403 chronic hepatitis C virus infection Diseases 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
230000004087 circulation Effects 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000008294 cold cream Substances 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
235000021310 complex sugar Nutrition 0.000 description 1
229940039231 contrast media Drugs 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
235000021019 cranberries Nutrition 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
201000011304 dilated cardiomyopathy 1A Diseases 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
210000004177 elastic tissue Anatomy 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
230000029578 entry into host Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000028023 exocytosis Effects 0.000 description 1
231100000573 exposure to toxins Toxicity 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
201000004098 fibrolamellar carcinoma Diseases 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229940014144 folate Drugs 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000010230 functional analysis Methods 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
230000035876 healing Effects 0.000 description 1
208000012727 heart conduction disease Diseases 0.000 description 1
208000018578 heart valve disease Diseases 0.000 description 1
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical class OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
PHNWGDTYCJFUGZ-UHFFFAOYSA-L hexyl phosphate Chemical compound CCCCCCOP([O-])([O-])=O PHNWGDTYCJFUGZ-UHFFFAOYSA-L 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
239000008311 hydrophilic ointment Substances 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
OFNXOACBUMGOPC-UHFFFAOYSA-N hydroxystreptomycin Natural products CNC1C(O)C(O)C(CO)OC1OC1C(C=O)(O)C(CO)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O OFNXOACBUMGOPC-UHFFFAOYSA-N 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000002570 interstitial cell Anatomy 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
229940028435 intralipid Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
OKPOKMCPHKVCPP-UHFFFAOYSA-N isoorientaline Natural products C1=C(O)C(OC)=CC(CC2C3=CC(OC)=C(O)C=C3CCN2C)=C1 OKPOKMCPHKVCPP-UHFFFAOYSA-N 0.000 description 1
238000005304 joining Methods 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
239000002960 lipid emulsion Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229960001078 lithium Drugs 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229960002523 mercuric chloride Drugs 0.000 description 1
LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
229960004963 mesalazine Drugs 0.000 description 1
238000010197 meta-analysis Methods 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
238000002493 microarray Methods 0.000 description 1
238000010208 microarray analysis Methods 0.000 description 1
230000001617 migratory effect Effects 0.000 description 1
238000003801 milling Methods 0.000 description 1
210000004115 mitral valve Anatomy 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
231100000381 nephrotoxic Toxicity 0.000 description 1
231100000637 nephrotoxin Toxicity 0.000 description 1
230000004766 neurogenesis Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
230000005305 organ development Effects 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
238000000059 patterning Methods 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000002991 phenoxazines Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
210000002706 plastid Anatomy 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
125000004585 polycyclic heterocycle group Chemical group 0.000 description 1
239000001259 polydextrose Substances 0.000 description 1
235000013856 polydextrose Nutrition 0.000 description 1
229940035035 polydextrose Drugs 0.000 description 1
229940068886 polyethylene glycol 300 Drugs 0.000 description 1
108010040003 polyglutamine Proteins 0.000 description 1
229920000155 polyglutamine Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
210000003240 portal vein Anatomy 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940116317 potato starch Drugs 0.000 description 1
229940071643 prefilled syringe Drugs 0.000 description 1
201000008312 primary pulmonary hypertension Diseases 0.000 description 1
230000002206 pro-fibrotic effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
238000001671 psychotherapy Methods 0.000 description 1
230000009325 pulmonary function Effects 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
239000001044 red dye Substances 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000023276 regulation of development, heterochronic Effects 0.000 description 1
210000002254 renal artery Anatomy 0.000 description 1
238000002271 resection Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
JTQHYPFKHZLTSH-UHFFFAOYSA-N reticulin Natural products COC1CC(OC2C(CO)OC(OC3C(O)CC(OC4C(C)OC(CC4OC)OC5CCC6(C)C7CCC8(C)C(CCC8(O)C7CC=C6C5)C(C)O)OC3C)C(O)C2OC)OC(C)C1O JTQHYPFKHZLTSH-UHFFFAOYSA-N 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
229910052895 riebeckite Inorganic materials 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
230000036573 scar formation Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000000862 serotonergic effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000000779 smoke Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
229960002256 spironolactone Drugs 0.000 description 1
108010068698 spleen exonuclease Proteins 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
230000000475 sunscreen effect Effects 0.000 description 1
239000000516 sunscreening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
208000037905 systemic hypertension Diseases 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
239000005451 thionucleotide Substances 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
230000007838 tissue remodeling Effects 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
201000006134 tongue cancer Diseases 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
125000000169 tricyclic heterocycle group Chemical group 0.000 description 1
208000037999 tubulointerstitial fibrosis Diseases 0.000 description 1
239000000107 tumor biomarker Substances 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
230000007306 turnover Effects 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
230000036325 urinary excretion Effects 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1
230000010388 wound contraction Effects 0.000 description 1
230000037314 wound repair Effects 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Oncology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Obesity (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)

TW106131684A 2011-04-25 2012-04-25 微型ｒｎａ化合物及調控ｍｉｒ－２１活性之方法 TWI698445B (zh)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US201161478767P	2011-04-25	2011-04-25
US61/478,767		2011-04-25
US201161565779P	2011-12-01	2011-12-01
US61/565,779		2011-12-01

Publications (2)

Publication Number	Publication Date
TW201811812A TW201811812A (zh)	2018-04-01
TWI698445B true TWI698445B (zh)	2020-07-11

Family

ID=46025979

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
TW106131684A TWI698445B (zh)	2011-04-25	2012-04-25	微型ｒｎａ化合物及調控ｍｉｒ－２１活性之方法
TW101114636A TWI607016B (zh)	2011-04-25	2012-04-25	微型ｒｎａ化合物及調控ｍｉｒ－２１活性之方法

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
TW101114636A TWI607016B (zh)	2011-04-25	2012-04-25	微型ｒｎａ化合物及調控ｍｉｒ－２１活性之方法

Country Status (30)

Country	Link
US (7)	US9181547B2 (fr)
EP (3)	EP3933040A1 (fr)
JP (2)	JP6320292B2 (fr)
KR (2)	KR102055172B1 (fr)
CN (3)	CN113249381A (fr)
AU (4)	AU2012249851B2 (fr)
BR (1)	BR112013027187A2 (fr)
CA (2)	CA2833615C (fr)
CL (1)	CL2013003105A1 (fr)
CO (1)	CO6821889A2 (fr)
CY (1)	CY1120304T1 (fr)
DK (2)	DK2702155T3 (fr)
EA (1)	EA025894B1 (fr)
ES (2)	ES2621863T3 (fr)
HR (2)	HRP20170557T2 (fr)
HU (2)	HUE031595T2 (fr)
IL (3)	IL229032B (fr)
LT (2)	LT3211082T (fr)
MX (5)	MX2013012452A (fr)
MY (2)	MY175336A (fr)
NZ (1)	NZ717921A (fr)
PH (1)	PH12013502199A1 (fr)
PL (2)	PL3211082T3 (fr)
PT (2)	PT3211082T (fr)
RS (1)	RS61775B1 (fr)
SG (1)	SG194636A1 (fr)
SI (2)	SI2702155T1 (fr)
TW (2)	TWI698445B (fr)
UA (1)	UA115652C2 (fr)
WO (1)	WO2012148952A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2503765T3 (es)	2004-11-12	2014-10-07	Asuragen, Inc.	Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES2621863T3 (es)	2011-04-25	2017-07-05	Regulus Therapeutics Inc.	Compuestos de microARN y métodos para modular la actividad de miR-21
WO2013153082A1 (fr) *	2012-04-10	2013-10-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés de traitement de la stéatose hépatique non alcoolique
AR090825A1 (es)	2012-04-25	2014-12-10	Regulus Therapeutics Inc	COMPUESTO DE microARN Y METODOS DE MODULACION DE LA ACTIVIDAD DE miR-21
UA116639C2 (uk)	2012-10-09	2018-04-25	Рег'Юлес Терап'Ютікс Інк.	Способи лікування синдрому альпорта
MY173826A (en)	2012-11-15	2020-02-24	Roche Innovation Ct Copenhagen As	Oligonucleotide conjugates
CA2908939C (fr) *	2013-05-01	2023-08-22	Balkrishen Bhat	Composes microarn et procedes permettant la modulation de l'activite de mir-122
WO2015061536A1 (fr) *	2013-10-25	2015-04-30	Regulus Therapeutics Inc.	Composés de microarn et procédés de modulation de l'activité de mir-21
KR101625755B1 (ko)	2013-11-18	2016-05-30	울산대학교 산학협력단	ｍｉＲＮＡ 스폰지 및 이의 용도
JP2017505623A (ja) *	2014-01-30	2017-02-23	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	生物切断性コンジュゲートを有するポリオリゴマー化合物
CN105734127A (zh) *	2016-02-29	2016-07-06	上海中医药大学	miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途
WO2017187426A1 (fr)	2016-04-29	2017-11-02	Aptamir Therapeutics, Inc.	Inhibition de l'arnmi mir-22 par apt-110
EP3548005A4 (fr)	2016-11-29	2020-06-17	Puretech Health LLC	Exosomes destinés à l'administration d'agents thérapeutiques
FI3684949T3 (fi)	2017-09-22	2024-07-17	Univ Washington	Solumolekyylien kombinatorinen in situ -leimaaminen
CN108148911B (zh) *	2018-03-02	2019-11-05	广州医科大学附属第二医院	miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用
TWI854980B (zh)	2018-05-08	2024-09-11	美商雷格勒斯治療公司	用於調節mir-122之微小rna化合物及方法
CN110747266A (zh) *	2018-07-23	2020-02-04	深圳先进技术研究院	miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用
CN109880907A (zh) *	2019-03-26	2019-06-14	中国人民解放军第八一医院	一种肝癌细胞侵袭转移的分子机制研究方法
US11965162B2 (en)	2020-04-16	2024-04-23	The Johns Hopkins University	MicroRNA and inhibitors thereof and methods of treatment
WO2022165092A1 (fr) *	2021-01-29	2022-08-04	Angion Biomedica Corp.	Méthodes de traitement de maladies fibrotiques
WO2025110217A1 (fr) *	2023-11-22	2025-05-30	国立大学法人東海国立大学機構	Agent prophylactique et/ou thérapeutique pour maladies kystiques rénales
CN120505413A (zh) *	2025-07-15	2025-08-19	湖南工程学院	一种基于引物交换反应和G-四链体检测AKI相关miRNA的探针体系及方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007027894A2 (fr) *	2005-08-29	2007-03-08	Isis Pharmaceuticals, Inc.	Composes antisens ayant une activite anti-microarn amelioree
WO2009106367A1 (fr) *	2008-02-27	2009-09-03	Julius Maximilians-Universität Würzburg	Microarn (miarn) et cibles en aval utilisés à des fins diagnostiques et thérapeutiques
EP2261333A2 (fr) *	2006-04-03	2010-12-15	Santaris Pharma A/S	Composition pharmaceutique comprenant des oligonucléotides antisens anti-ARNmi

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69935853T2 (de)	1998-05-22	2008-01-10	Boys Town National Research Hospital, Omaha	Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
US20060008817A1 (en) *	2000-12-08	2006-01-12	Invitrogen Corporation	Methods and compositions for generating recombinant nucleic acid molecules
CA2937159C (fr)	2001-09-28	2017-11-28	Thomas Tuschl	Molecules de micro-arn
WO2004041889A2 (fr)	2002-11-05	2004-05-21	Isis Pharmaceuticals, Inc.	Composes oligomeres renfermant un substitut de sucre polycyclique et compositions intervenant dans la modulation genique
US20050124591A1 (en)	2003-07-29	2005-06-09	Jin Tian	Use of vitamin Ds to treat kidney disease
EP1648914A4 (fr) *	2003-07-31	2009-12-16	Regulus Therapeutics Inc	Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
EP1661905B9 (fr)	2003-08-28	2012-12-19	IMANISHI, Takeshi	Nouveaux acides nucleiques artificiels de type a liaison n-o reticulee
WO2006020768A2 (fr)	2004-08-10	2006-02-23	Alnylam Pharmaceuticals, Inc.	Oligonucleotides chimiquement modifies
US20080187508A1 (en)	2004-09-08	2008-08-07	Boys Town National Research Hospital	Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12
ES2503765T3 (es)	2004-11-12	2014-10-07	Asuragen, Inc.	Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
EP1838870A2 (fr)	2004-12-29	2007-10-03	Exiqon A/S	Nouvelles compositions d'oligonucleotides et sequences de sondes utiles pour la detection et l'analyse de microarn et de leurs marn cibles
US6995235B1 (en)	2005-05-02	2006-02-07	Univation Technologies, Llc	Methods of producing polyolefins and films therefrom
EP2388328A1 (fr)	2006-01-27	2011-11-23	Isis Pharmaceuticals, Inc.	Composés oligomères et compositions pour une utilisation dans la modulation de micro ARN
EP1984381B1 (fr)	2006-01-27	2010-09-29	Isis Pharmaceuticals, Inc.	Analogues d'acides nucleiques bicycliques modifies en position 6
CA3042781C (fr) *	2006-04-03	2021-10-19	Roche Innovation Center Copenhagen A/S	Composition pharmaceutique comprenant des oligonucleotides antisens anti-microarn
DK2068886T3 (da)	2006-10-03	2013-11-18	Tekmira Pharmaceuticals Corp	Lipidholdige præparater
EP2476762B1 (fr)	2006-10-09	2014-01-08	Julius-Maximilians-Universität Würzburg	Micro-ARN (miARN) pour le diagnostic et le traitement de maladies cardiaques
AU2007333107A1 (en)	2006-12-08	2008-06-19	Asuragen, Inc.	miR-21 regulated genes and pathways as targets for therapeutic intervention
WO2008086807A2 (fr)	2007-01-19	2008-07-24	Exiqon A/S	Apport cellulaire médié d'oligonucléotides de lna
WO2008150729A2 (fr)	2007-05-30	2008-12-11	Isis Pharmaceuticals, Inc.	Analogues d'acides nucléiques bicycliques pontés par aminométhylène n-substitué
EP2173760B2 (fr)	2007-06-08	2015-11-04	Isis Pharmaceuticals, Inc.	Analogues d'acide nucléique bicyclique carbocylique
WO2008151631A2 (fr)	2007-06-15	2008-12-18	Exiqon A/S	Utilisation de courts oligonucléotides pour des expériences à redondance de réactif dans une analyse fonctionnelle d'arn
DK2176280T4 (en)	2007-07-05	2015-07-20	Isis Pharmaceuticals Inc	6-Disubstituerede bicykliske nukleinsyreanaloge
CA2701547C (fr) *	2007-10-04	2020-03-10	Santaris Pharma A/S	Oligonucleotiques qui ciblent et inhibent les micro arn
WO2009058907A2 (fr) *	2007-10-29	2009-05-07	Isis Pharmaceuticals, Inc.	Ciblage de microarn pour le traitement du cancer du foie
WO2009091972A2 (fr)	2008-01-18	2009-07-23	Alnylam Pharmaceuticals, Inc.	Oligonucléotides modifiés chimiquement et petites molécules à utiliser dans la réduction des taux d'activité de microarn et leurs utilisations
EP2249874A1 (fr)	2008-02-08	2010-11-17	ProSensa Holding BV	Méthodes et moyens pour traiter les affections génétiques associées à l instabilité de répétition d adn
US8404659B2 (en)	2008-03-07	2013-03-26	Santaris Pharma A/S	Pharmaceutical compositions for treatment of MicroRNA related diseases
AU2010218147A1 (en)	2009-02-26	2011-10-20	The Government Of The United States Of America As Represented By The Secretary Of The Dept. Of Health & Human Services	MicroRNAs in never-smokers and related materials and methods
MX2011013176A (es)	2009-06-08	2012-04-30	Miragen Therapeutics	Motivos de modificación química para inhibidores y miméticos del miarn.
WO2011126842A2 (fr)	2010-03-30	2011-10-13	Regulus Therapeutics Inc.	Ciblage de micro-arn pour le traitement de troubles cardiaques
ES2621863T3 (es)	2011-04-25	2017-07-05	Regulus Therapeutics Inc.	Compuestos de microARN y métodos para modular la actividad de miR-21
WO2013013165A2 (fr)	2011-07-21	2013-01-24	The Trustees Of The University Of Pennsylvania	Utilisation de composés d'acide nucléique bloqué (lna) pour l'inhibition thérapeutique de mir-21 dans le lupus érythémateux systémique
AR090825A1 (es)	2012-04-25	2014-12-10	Regulus Therapeutics Inc	COMPUESTO DE microARN Y METODOS DE MODULACION DE LA ACTIVIDAD DE miR-21
EP3354734B1 (fr)	2012-06-21	2020-06-10	Miragen Therapeutics, Inc.	Inhibiteurs à base d'oligonucléotides comprenant un motif d'acide nucléique bloqué
JP6352269B2 (ja)	2012-09-26	2018-07-04	ミルクスセラピューティクスアクティーゼルスカブＭｉｒｒｘＴｈｅｒａｐｅｕｔｉｃｓＡ／Ｓ	オフターゲットプロファイルの改善されたオリゴマー
UA116639C2 (uk)	2012-10-09	2018-04-25	Рег'Юлес Терап'Ютікс Інк.	Способи лікування синдрому альпорта

2012
- 2012-04-25 ES ES12718549.4T patent/ES2621863T3/es active Active
- 2012-04-25 MX MX2013012452A patent/MX2013012452A/es unknown
- 2012-04-25 MY MYPI2013003885A patent/MY175336A/en unknown
- 2012-04-25 WO PCT/US2012/034880 patent/WO2012148952A1/fr not_active Ceased
- 2012-04-25 PT PT171537244T patent/PT3211082T/pt unknown
- 2012-04-25 ES ES17153724T patent/ES2868950T3/es active Active
- 2012-04-25 NZ NZ717921A patent/NZ717921A/en unknown
- 2012-04-25 MY MYPI2017000706A patent/MY187685A/en unknown
- 2012-04-25 HU HUE12718549A patent/HUE031595T2/en unknown
- 2012-04-25 TW TW106131684A patent/TWI698445B/zh active
- 2012-04-25 SI SI201230924A patent/SI2702155T1/sl unknown
- 2012-04-25 EP EP21157334.0A patent/EP3933040A1/fr not_active Withdrawn
- 2012-04-25 LT LTEP17153724.4T patent/LT3211082T/lt unknown
- 2012-04-25 KR KR1020137031227A patent/KR102055172B1/ko active Active
- 2012-04-25 HR HRP20170557TT patent/HRP20170557T2/hr unknown
- 2012-04-25 EP EP12718549.4A patent/EP2702155B9/fr active Active
- 2012-04-25 MX MX2019003090A patent/MX393138B/es unknown
- 2012-04-25 US US14/111,976 patent/US9181547B2/en active Active
- 2012-04-25 CA CA2833615A patent/CA2833615C/fr active Active
- 2012-04-25 CN CN202110383567.1A patent/CN113249381A/zh active Pending
- 2012-04-25 EP EP17153724.4A patent/EP3211082B1/fr active Active
- 2012-04-25 HU HUE17153724A patent/HUE054129T2/hu unknown
- 2012-04-25 PT PT127185494T patent/PT2702155T/pt unknown
- 2012-04-25 TW TW101114636A patent/TWI607016B/zh active
- 2012-04-25 UA UAA201312414A patent/UA115652C2/uk unknown
- 2012-04-25 BR BR112013027187A patent/BR112013027187A2/pt not_active Application Discontinuation
- 2012-04-25 DK DK12718549.4T patent/DK2702155T3/en active
- 2012-04-25 KR KR1020197015054A patent/KR20190063482A/ko not_active Ceased
- 2012-04-25 CN CN201280031285.4A patent/CN103620035B/zh active Active
- 2012-04-25 EA EA201391492A patent/EA025894B1/ru not_active IP Right Cessation
- 2012-04-25 PL PL17153724T patent/PL3211082T3/pl unknown
- 2012-04-25 DK DK17153724.4T patent/DK3211082T3/da active
- 2012-04-25 AU AU2012249851A patent/AU2012249851B2/en active Active
- 2012-04-25 CA CA3165397A patent/CA3165397A1/fr active Pending
- 2012-04-25 JP JP2014508494A patent/JP6320292B2/ja active Active
- 2012-04-25 CN CN202110384864.8A patent/CN113151272A/zh active Pending
- 2012-04-25 PH PH1/2013/502199A patent/PH12013502199A1/en unknown
- 2012-04-25 RS RS20210552A patent/RS61775B1/sr unknown
- 2012-04-25 SI SI201231913T patent/SI3211082T1/sl unknown
- 2012-04-25 LT LTEP12718549.4T patent/LT2702155T/lt unknown
- 2012-04-25 SG SG2013079454A patent/SG194636A1/en unknown
- 2012-04-25 PL PL12718549T patent/PL2702155T3/pl unknown
- 2012-04-25 US US13/455,337 patent/US20120270928A1/en active Pending
2013
- 2013-10-23 IL IL229032A patent/IL229032B/en active IP Right Grant
- 2013-10-23 MX MX2022006595A patent/MX2022006595A/es unknown
- 2013-10-23 MX MX2022000212A patent/MX2022000212A/es unknown
- 2013-10-23 MX MX2019003089A patent/MX2019003089A/es unknown
- 2013-10-25 CL CL2013003105A patent/CL2013003105A1/es unknown
- 2013-10-30 CO CO13257480A patent/CO6821889A2/es unknown
2014
- 2014-07-28 US US14/444,406 patent/US8912161B2/en active Active
2015
- 2015-10-14 US US14/883,055 patent/US9790496B2/en active Active
2017
- 2017-04-25 CY CY20171100460T patent/CY1120304T1/el unknown
- 2017-08-29 AU AU2017219156A patent/AU2017219156B2/en active Active
- 2017-09-14 US US15/704,749 patent/US20180155719A1/en not_active Abandoned
2018
- 2018-04-02 JP JP2018070694A patent/JP2018121646A/ja active Pending
2019
- 2019-05-08 IL IL266529A patent/IL266529A/en unknown
2020
- 2020-01-24 US US16/751,402 patent/US20200291400A1/en not_active Abandoned
- 2020-02-26 AU AU2020201403A patent/AU2020201403A1/en not_active Abandoned
- 2020-03-18 IL IL273381A patent/IL273381A/en unknown
2021
- 2021-04-19 HR HRP20210616TT patent/HRP20210616T1/hr unknown
- 2021-08-18 US US17/405,482 patent/US12331294B2/en active Active
2022
- 2022-05-06 AU AU2022203067A patent/AU2022203067A1/en not_active Abandoned

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007027894A2 (fr) *	2005-08-29	2007-03-08	Isis Pharmaceuticals, Inc.	Composes antisens ayant une activite anti-microarn amelioree
EP2261333A2 (fr) *	2006-04-03	2010-12-15	Santaris Pharma A/S	Composition pharmaceutique comprenant des oligonucléotides antisens anti-ARNmi
WO2009106367A1 (fr) *	2008-02-27	2009-09-03	Julius Maximilians-Universität Würzburg	Microarn (miarn) et cibles en aval utilisés à des fins diagnostiques et thérapeutiques

Also Published As

Publication number	Publication date
BR112013027187A2 (pt)	2017-06-06
HUE031595T2 (en)	2017-07-28
DK2702155T3 (en)	2017-05-01
AU2022203067A1 (en)	2022-05-26
IL229032A0 (en)	2013-12-31
US20200291400A1 (en)	2020-09-17
MY187685A (en)	2021-10-11
JP2014518619A (ja)	2014-08-07
HRP20170557T1 (hr)	2017-06-16
HRP20170557T2 (hr)	2020-02-21
EP3933040A1 (fr)	2022-01-05
IL229032B (en)	2021-01-31
HRP20210616T1 (hr)	2021-05-28
HK1243130A1 (en)	2018-07-06
EP2702155B9 (fr)	2020-01-01
EP2702155B1 (fr)	2017-02-01
HUE054129T2 (hu)	2021-08-30
MX2022000212A (es)	2022-04-01
IL273381A (en)	2020-05-31
IL266529A (en)	2019-07-31
PT3211082T (pt)	2021-04-28
TW201300404A (zh)	2013-01-01
SG194636A1 (en)	2013-12-30
US12331294B2 (en)	2025-06-17
EP2702155A1 (fr)	2014-03-05
WO2012148952A1 (fr)	2012-11-01
CN113249381A (zh)	2021-08-13
AU2017219156A1 (en)	2017-09-21
MX393138B (es)	2025-03-24
US9181547B2 (en)	2015-11-10
PL2702155T3 (pl)	2017-09-29
US20140329887A1 (en)	2014-11-06
CY1120304T1 (el)	2019-07-10
ES2868950T3 (es)	2021-10-22
EA025894B1 (ru)	2017-02-28
CA3165397A1 (fr)	2012-11-01
CA2833615A1 (fr)	2012-11-01
CN103620035A (zh)	2014-03-05
CO6821889A2 (es)	2013-12-31
MX2022006595A (es)	2022-07-01
NZ616748A (en)	2016-03-31
US20180155719A1 (en)	2018-06-07
LT3211082T (lt)	2021-05-10
US9790496B2 (en)	2017-10-17
MY175336A (en)	2020-06-19
PH12013502199A1 (en)	2014-01-27
TWI607016B (zh)	2017-12-01
US8912161B2 (en)	2014-12-16
AU2012249851A1 (en)	2013-10-31
AU2012249851B2 (en)	2017-06-08
AU2020201403A1 (en)	2020-03-12
US20120270928A1 (en)	2012-10-25
CN113151272A (zh)	2021-07-23
ES2621863T9 (es)	2020-02-13
US20160138016A1 (en)	2016-05-19
JP2018121646A (ja)	2018-08-09
CA2833615C (fr)	2022-08-30
ES2621863T3 (es)	2017-07-05
MX2019003090A (es)	2019-07-18
KR20140033062A (ko)	2014-03-17
US20140107183A1 (en)	2014-04-17
RS61775B1 (sr)	2021-05-31
KR20190063482A (ko)	2019-06-07
US20220098583A1 (en)	2022-03-31
MX2013012452A (es)	2014-11-21
NZ717921A (en)	2017-09-29
EA201391492A1 (ru)	2014-04-30
PL3211082T3 (pl)	2021-08-02
LT2702155T (lt)	2017-05-10
CL2013003105A1 (es)	2014-08-01
SI2702155T1 (sl)	2017-07-31
EP3211082B1 (fr)	2021-02-17
PT2702155T (pt)	2017-04-03
CN103620035B (zh)	2021-04-23
EP3211082A1 (fr)	2017-08-30
DK3211082T3 (da)	2021-05-10
AU2017219156B2 (en)	2020-01-02
MX2019003089A (es)	2019-07-18
KR102055172B1 (ko)	2020-01-23
AU2012249851A8 (en)	2013-11-14
UA115652C2 (uk)	2017-12-11
SI3211082T1 (sl)	2021-08-31
TW201811812A (zh)	2018-04-01
JP6320292B2 (ja)	2018-05-09

Publication	Publication Date	Title
TWI698445B (zh)	2020-07-11	微型ｒｎａ化合物及調控ｍｉｒ－２１活性之方法
TWI647235B (zh)	2019-01-11	微型ｒｎａ（ｍｉｃｒｏｒｎａ）化合物及調節ｍｉｒ－２１活性之方法
HK40065959A (en)	2022-08-12	Microrna compounds and methods for modulating mir-21 activity
HK1243130B (en)	2021-09-10	Microrna compounds and methods for modulating mir-21 activity
HK1195585B (en)	2018-03-09	Microrna compounds and methods for modulating mir-21 activity
HK1195585A (en)	2014-11-14	Microrna compounds and methods for modulating mir-21 activity
NZ616748B2 (en)	2016-07-01	Microrna compounds and methods for modulating mir-21 activity
HK1207115B (en)	2019-11-01	Microrna compounds and methods for modulating mir-21 activity